The value of the transaction is $240 million which will be financed from existing cash and debt facilities. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Investors Andrew Swift Smith & Nephew +44 (0) 20 7960 2285 Media Charles Reynolds Smith & Nephew +44 (0) 1923 477314 Ben Atwell / Andrew Ward FTI Consulting +44 (0) 20 3727 1000 Smith+Nephew expects around 300 employees to join once the acquisition is completed, with the business operating from facilities in Austin, Texas and Lyon, France. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru®. The business generated revenue of $90 million in 2019 and traded at a small loss. The focused extremities commercial channel includes a specialised sales force and distributors, predominantly in the US as well as Canada and Europe. For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter , LinkedIn , Instagram or Facebook . Telescoping boxes reduce shipping costs and emissions, Curaçao achieves Sustainability Standards Award, First European commercial surgical training facility accredited by RCS, Helping patients on low incomes and in rural areas, Supporting South African Children in Need, Transforming negative pressure wound therapy, Smith+Nephew expands in higher-growth extremities segment through planned acquisition of Integra LifeSciences’ Extremity Orthopaedics business. Certain marks registered US Patent and Trademark Office. If you have allowed cookies in the settings of your web browser and you continue to use our website, you agree. Peter Ligotti, Senior Vice President, Extremity Orthopaedics, Integra LifeSciences, said: “We are looking forward to joining an organisation that is committed to growing and expanding its orthopaedic product portfolio. The value of the transaction is $240 million which will be financed from existing cash and debt facilities. The focused extremities commercial channel includes a specialised sales force and distributors, predominantly in the US as well as Canada and Europe. Telescoping boxes reduce shipping costs and emissions, Curaçao achieves Sustainability Standards Award, First European commercial surgical training facility accredited by RCS, Helping patients on low incomes and in rural areas, Supporting South African Children in Need, Transforming negative pressure wound therapy. For further information, please contact rns@lseg.com or visit www.rns.com. The portfolio is highly complementary to Smith+Nephew’s existing orthopaedics offering, in particular providing entry into the shoulder replacement and foot and ankle segments. For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. The business is expected to deliver double-digit revenue growth and be slightly dilutive to trading profit in 2021 and 2022. Annual sales in 2018 were $4.9 billion. Skip Kiil, President, Global Orthopaedics at Smith+Nephew, said: "Integra's Extremity Orthopaedics business is an established global player in the rapidly growing extremities segment, including total shoulder replacement, and has a well-regarded specialised sales channel and a strong pipeline of new products. Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. The business generated revenue of $90 million in 2019 and traded at a small loss. A total of 8 … This document may contain forward-looking statements that may or may not prove accurate. The Extremity Orthopaedics R&D pipeline includes a next-generation shoulder replacement system, which is expected to be ready for full commercial launch in 2022. This website uses cookies to help you get the most out of your experience during your visit, and we can improve the content served to you by collecting statistical information. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. ‡ In these countries please contact our distributor. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. The acquisition supports Smith+Nephew’s strategy to invest in higher-growth segments. Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. This document may contain forward-looking statements that may or may not prove accurate. The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

.

Dillian Whyte Weight, What Is Beto O'rourke Doing Now, Ascension Providence Patient Portal, Paul Valery Quotes, Door Security Camera, Russian Gypsy Music, Jorge Masvidal Record, Falcon Heavy Test Flight, How To Get A Message To Mitch Mcconnell, Edward Mulhare, Juan Cuadrado Wife, Senegal National Team, Teofimo Lopez Vs Lomachenko Fight Date, Golem Meaning In Telugu, Fast Money, Gambro Dialysis Machine Models, Ethicon Vicryl Suture, Switzerland Healthcare System 2019, Andre Ward Next Fight, Matt Gaetz News, Without Limits Quotes, Half-life Alyx Meme, Welding Engineer Degree Online, Under The Big Top Carcassonne, Castle Rock, Wa, Castle And Castle Nigerian Series,